Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease

ConditionParkinson Disease

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18-85

SponsorProgenaBiome

About this trial

FMT may significantly improve quality of life and Parkinson Disease (PD) symptom severity measurements. We hypothesize that gut microbial dysbiosis is a major contributing factor in Parkinson's disease.

Eligibility criteria

Qualifiers

Individuals diagnosed with PD

Disqualifiers

Non-PD individuals

Trial design

Treatments tested in this trial

Fecal Microbiota Transplant

Treatment groups

10 Participants

are divided into 1 treatment group

Sponsors and collaborators

ProgenaBiome

Lead sponsor

Source ClinicalTrials.gov